Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 25,582 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 25,582 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $26.02, for a total transaction of $665,643.64. Following the sale, the chief executive officer directly owned 350,987 shares of the company’s stock, valued at approximately $9,132,681.74. This trade represents a 6.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Down 1.1%

MAZE opened at $26.05 on Thursday. The firm has a 50 day moving average price of $29.69 and a 200 day moving average price of $37.61. The company has a market cap of $1.44 billion, a PE ratio of -10.30 and a beta of 2.50. Maze Therapeutics, Inc. has a 1 year low of $9.73 and a 1 year high of $53.65. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. Sell-side analysts expect that Maze Therapeutics, Inc. will post -2.74 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on MAZE shares. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Guggenheim raised their price target on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. BTIG Research reissued a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Wedbush raised their price objective on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research note on Monday, March 16th. Finally, JPMorgan Chase & Co. raised their price objective on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 31st. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and an average target price of $66.00.

Institutional Investors Weigh In On Maze Therapeutics

A number of hedge funds have recently added to or reduced their stakes in MAZE. Janus Henderson Group PLC raised its stake in shares of Maze Therapeutics by 318.0% during the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after purchasing an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Maze Therapeutics by 27.1% during the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock valued at $70,307,000 after purchasing an additional 362,060 shares in the last quarter. Woodline Partners LP grew its holdings in Maze Therapeutics by 10.0% during the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after acquiring an additional 94,529 shares during the period. Marshall Wace LLP grew its holdings in Maze Therapeutics by 9.0% during the fourth quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock worth $35,111,000 after acquiring an additional 69,771 shares during the period. Finally, ArrowMark Colorado Holdings LLC grew its holdings in Maze Therapeutics by 40.8% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 767,383 shares of the company’s stock worth $31,793,000 after acquiring an additional 222,251 shares during the period.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.